BR9904150A - Composições de proteìnas estabilizadas - Google Patents

Composições de proteìnas estabilizadas

Info

Publication number
BR9904150A
BR9904150A BR9904150-2A BR9904150A BR9904150A BR 9904150 A BR9904150 A BR 9904150A BR 9904150 A BR9904150 A BR 9904150A BR 9904150 A BR9904150 A BR 9904150A
Authority
BR
Brazil
Prior art keywords
protein compositions
stabilized protein
mammals
stabilized
csf
Prior art date
Application number
BR9904150-2A
Other languages
English (en)
Inventor
Peter Connor Canning
Barbara Jean Kamicker
Kasra Kasraian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9904150A publication Critical patent/BR9904150A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES DE PROTEìNAS ESTABILIZADAS"<D>. Esta invenção refere-se à composições de proteínas estabilizadas, métodos para preparação de tais composições de proteínas estabilizadas, formas de dosagem para administração de tais composições de proteínas estabilizadas a mamíferos e métodos para prevenção ou tratamento em mamíferos através da administração de tais composições de proteínas a mamíferos. Mais particularmente, as composições de proteínas estabilizadas da presente invenção contem quantidades terapeuticamente eficazes de G-CSF, tal como o G-CSF bovino, em combinação com um tampão estabilizador, tais como HEPES, TES ou TRICINE, para o tratamento e prevenção de infecções, incluindo mastite em gado.
BR9904150-2A 1998-08-17 1999-08-17 Composições de proteìnas estabilizadas BR9904150A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9687698P 1998-08-17 1998-08-17

Publications (1)

Publication Number Publication Date
BR9904150A true BR9904150A (pt) 2000-12-26

Family

ID=22259521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9904150-2A BR9904150A (pt) 1998-08-17 1999-08-17 Composições de proteìnas estabilizadas

Country Status (16)

Country Link
US (1) US20050232898A1 (pt)
EP (1) EP0988861B1 (pt)
JP (1) JP3641170B2 (pt)
CN (1) CN1250282C (pt)
AR (1) AR016504A1 (pt)
AT (1) ATE260674T1 (pt)
AU (2) AU767431B2 (pt)
BR (1) BR9904150A (pt)
CA (1) CA2280449A1 (pt)
DE (1) DE69915204T2 (pt)
DK (1) DK0988861T3 (pt)
ES (1) ES2216447T3 (pt)
NZ (2) NZ510140A (pt)
PT (1) PT988861E (pt)
TW (1) TWI221773B (pt)
ZA (1) ZA995201B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200401573T4 (tr) * 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
ITBA20020032A1 (it) * 2002-09-24 2004-03-25 Bio D Soc Metodo per stabilizzare le proteine per la conservazione ad alte temperature.
WO2005025593A2 (en) * 2003-05-09 2005-03-24 Schering Aktiengesellschaft Treatment of inflammatory respiratory diseases
CN1878570B (zh) * 2003-11-04 2010-10-06 力奇制药公司 包含粒细胞集落形成刺激因子的稳定的药物组合物
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
EP1691798A1 (en) * 2003-12-09 2006-08-23 Alcon, Inc. Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions
EP2494983B1 (en) * 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
ES2383303T3 (es) * 2005-11-10 2012-06-20 Chemi S.P.A. Formulaciones de inhibidores de la liberación prolongada de la hormona del crecimiento análogos de la somatostatina
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
JP5623743B2 (ja) 2006-10-20 2014-11-12 アムジエン・インコーポレーテツド 安定なポリペプチド製剤
PT2076243E (pt) 2007-08-27 2014-12-05 Ratiopharm Gmbh Formulação líquida de g-csf
MY151252A (en) * 2007-10-09 2014-04-30 Hercules Inc Crosslinker-containing adhesive compositions
MX2011000859A (es) * 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
TWI480288B (zh) * 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
ITMI20120338A1 (it) * 2012-03-06 2013-09-07 Dr Andrea Bignotti Preparato terapeutico e procedimento di preparazione di detto preparato terapeutico
GB2516808A (en) 2013-05-31 2015-02-11 Innova Biosciences Ltd Antibody composition and buffer system therefor
US11464831B2 (en) 2015-01-05 2022-10-11 Cornell University Compositions and methods using IL-8 for improving health of mammals
US10500253B2 (en) 2015-01-05 2019-12-10 Cornell University Compositions and methods using IL-8 to improve milk production and reproductive health in mammals
ES2952744T3 (es) 2016-12-15 2023-11-03 Nestle Sa Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía
EP3771463A1 (en) 2019-07-29 2021-02-03 Ludwig-Maximilians-Universität München Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
FI900178A0 (fi) * 1988-05-13 1990-01-12 Amgen Inc Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur.
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof

Also Published As

Publication number Publication date
HK1026151A1 (en) 2000-12-08
NZ510140A (en) 2005-01-28
AU767431B2 (en) 2003-11-13
TWI221773B (en) 2004-10-11
CN1250282C (zh) 2006-04-12
EP0988861B1 (en) 2004-03-03
PT988861E (pt) 2004-06-30
NZ337258A (en) 2001-04-27
AU4450199A (en) 2000-03-09
CA2280449A1 (en) 2000-02-17
DE69915204D1 (de) 2004-04-08
JP3641170B2 (ja) 2005-04-20
JP2000063264A (ja) 2000-02-29
DK0988861T3 (da) 2004-04-19
ATE260674T1 (de) 2004-03-15
CN1250668A (zh) 2000-04-19
ZA995201B (en) 2001-02-16
DE69915204T2 (de) 2004-07-29
EP0988861A1 (en) 2000-03-29
ES2216447T3 (es) 2004-10-16
AU2004200568A1 (en) 2004-03-11
AR016504A1 (es) 2001-07-04
US20050232898A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
AP9801420A0 (en) Novel macrolides.
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
BRPI0411016A (pt) composições antisépticas, processos e sistemas
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
PA8486001A1 (es) Composiciones de celecoxib
BR9911071A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépticos e/ou agentes promotores da cura de feridas no trato respiratório superior e/ou no ouvido
AR016504A1 (es) Composicion proteica estabilizada, forma farmaceutica de dosificacion, un metodo para preparar una forma farmaceutica de dosificacion, uso de la composicion proteica en la fabricacion de medicamentos y kit
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
BR0312286A (pt) pró-medicamentos de 2&#39; e 3&#39; - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0004884A (pt) Composições acaricidas
ATE316794T1 (de) Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
BR0215650A (pt) Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica
AP2001002142A0 (en) 13-membered azalides and their use as antibiotic agents.
BR9914419A (pt) Terapia para melhoria da percepção
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
BR9813317A (pt) Composto, composição farmacêutica para tratar infecções bacterianas, e, processos para tratar infecções bacterianas, e para preparar um composto
BR0110382A (pt) Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR9916432A (pt) Compostos de triazinona para o tratamento de doenças devido ao sarcosystis, neospora e ao toxoplasma
PT817646E (pt) Metodos de tratamento da inflamacao e formulacoes para esse fim

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SE DE PROSSEGUIMENTO AO EXAME TECNICO, A REQUERENTE DEVERA COMPLEMENTAR O VALOR DA TAXA DE EXAME REFERENTE A 2 (DUAS) REIVINDICACOES EXCEDENTES QUE FORAM APRESENTADAS ATRAVES DA PETICAO NO 037754 DE 12/07/2002.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements